BSE Live
Apr 10, 16:01Prev. Close
730.05
Open Price
738.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 10, 15:50Prev. Close
725.80
Open Price
736.70
Bid Price (Qty.)
732.00 (97)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Albert David (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 24.01 | 22.03 | 15.00 | 13.37 | 19.00 | |
| Diluted EPS (Rs.) | 24.01 | 22.03 | 15.00 | 13.37 | 19.00 | |
| Cash EPS (Rs.) | 51.01 | 41.40 | 33.81 | 30.49 | 36.46 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 162.64 | 158.29 | 142.11 | 132.38 | 124.25 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 162.64 | 158.29 | 142.11 | 132.38 | 124.25 | |
| Dividend / Share(Rs.) | 5.50 | 5.00 | 4.50 | 4.50 | 4.50 | |
| Revenue from Operations/Share (Rs.) | 563.81 | 512.11 | 465.11 | 404.95 | 384.96 | |
| PBDIT/Share (Rs.) | 67.25 | 58.01 | 47.94 | 42.85 | 51.13 | |
| PBIT/Share (Rs.) | 40.24 | 38.63 | 29.13 | 25.72 | 33.67 | |
| PBT/Share (Rs.) | 35.51 | 32.35 | 23.45 | 19.69 | 28.75 | |
| Net Profit/Share (Rs.) | 24.01 | 22.03 | 15.00 | 13.37 | 19.00 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 11.92 | 11.32 | 10.30 | 10.58 | 13.28 | |
| PBIT Margin (%) | 7.13 | 7.54 | 6.26 | 6.35 | 8.74 | |
| PBT Margin (%) | 6.29 | 6.31 | 5.04 | 4.86 | 7.46 | |
| Net Profit Margin (%) | 4.25 | 4.30 | 3.22 | 3.30 | 4.93 | |
| Return on Networth / Equity (%) | 14.75 | 13.91 | 10.55 | 10.09 | 15.29 | |
| Return on Capital Employed (%) | 12.51 | 10.83 | 6.68 | 8.21 | 11.30 | |
| Return on Assets (%) | 7.08 | 6.35 | 4.08 | 3.76 | 5.50 | |
| Total Debt/Equity (X) | 0.30 | 0.44 | 0.47 | 0.49 | 0.58 | |
| Asset Turnover Ratio (%) | 166.33 | 147.61 | 126.64 | 113.94 | 111.53 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.39 | 1.32 | 1.35 | 1.06 | 1.14 | |
| Quick Ratio (X) | 0.76 | 0.79 | 0.83 | 0.69 | 0.79 | |
| Inventory Turnover Ratio (X) | 6.17 | 6.78 | 6.24 | 5.74 | 6.33 | |
| Dividend Payout Ratio (NP) (%) | 22.91 | 22.69 | 30.00 | 33.66 | 23.67 | |
| Dividend Payout Ratio (CP) (%) | 10.78 | 12.07 | 13.31 | 14.75 | 12.34 | |
| Earnings Retention Ratio (%) | 77.09 | 77.31 | 70.00 | 66.34 | 76.33 | |
| Cash Earnings Retention Ratio (%) | 89.22 | 87.93 | 86.69 | 85.25 | 87.66 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 175.01 | 96.79 | 74.70 | 73.06 | 83.95 | |
| EV/Net Operating Revenue (X) | 0.54 | 0.33 | 0.28 | 0.32 | 0.38 | |
| EV/EBITDA (X) | 4.56 | 2.92 | 2.73 | 2.99 | 2.88 | |
| MarketCap/Net Operating Revenue (X) | 0.49 | 0.23 | 0.19 | 0.21 | 0.30 | |
| Retention Ratios (%) | 77.08 | 77.30 | 69.99 | 66.33 | 76.32 | |
| Price/BV (X) | 1.69 | 0.73 | 0.63 | 0.63 | 0.94 | |
| Price/Net Operating Revenue | 0.49 | 0.23 | 0.19 | 0.21 | 0.30 | |
| Earnings Yield | 0.09 | 0.19 | 0.17 | 0.16 | 0.16 |
25.02.2026
Albert David Standalone December 2025 Net Sales at Rs 89.93 crore, up 8.24% Y-o-Y
13.11.2025
Albert David Standalone September 2025 Net Sales at Rs 87.24 crore, down 11.37% Y-o-Y
05.08.2025
Albert David Standalone June 2025 Net Sales at Rs 70.57 crore, down 21.03% Y-o-Y
13.05.2025
Albert David Standalone March 2025 Net Sales at Rs 74.89 crore, down 15.9% Y-o-Y
25.02.2026
Albert David Standalone December 2025 Net Sales at Rs 89.93 crore, up 8.24% Y-o-Y
13.11.2025
Albert David Standalone September 2025 Net Sales at Rs 87.24 crore, down 11.37% Y-o-Y
05.08.2025
Albert David Standalone June 2025 Net Sales at Rs 70.57 crore, down 21.03% Y-o-Y
13.05.2025
Albert David Standalone March 2025 Net Sales at Rs 74.89 crore, down 15.9% Y-o-Y
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth